Veteran oncology regulator brings more than 25 years of FDA experience as Siren advances SRN-101 into clinical developmentSAN FRANCISCO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Siren Biotechnology, a ...
Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...
Zacks Investment Research on MSN
PDS Biotechnology (PDSB) upgraded to buy: What does it mean for the stock?
PDS Biotechnology (PDSB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
The Defense Innovation Networking Group (D!NG) today announced that the submission window is officially open for the ...
Sana Biotechnology trades at a steep discount despite promising T1D assets UP421 and SC451. Check out why SANA stock is a buy ...
Vir Biotechnology, entered a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN dual-masked T-cell engager development candidates target ...
Vir Biotechnology ( ($VIR) ) has provided an update. On October 9, 2026, Vir Biotechnology entered a collaboration and license agreement with Gilead Sciences to ...
Zacks Investment Research on MSN
Is Invesco Biotechnology & Genome ETF (PBE) a strong ETF right now?
The Invesco Biotechnology & Genome ETF (PBE) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. What ...
Nautilus Biotechnology, Inc. is currently listed on NASDAQ under NAUT. One share of NAUT stock can currently be purchased for approximately $2.08. Is Nautilus Biotechnology, Inc. listed on the NASDAQ ...
Vir Biotechnology has appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026 ...
Biotechnology is a curious marriage of two seemingly disparate worlds. On one end, we have living organisms—wild, unpredictable celestial creations that can probably never be understood or appreciated ...
FHLC offers broader sector exposure at a 0.08% expense ratio, compared with IBB's concentrated biotech focus at 0.44%, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results